List view / Grid view
23 October 2013 | By Chandler Chicco Agency
Positive opinion paves the way for a second aesthetic indication for VISTABEL® in 29 European countries...
22 October 2013 | By Novartis
"Novartis delivered strong sales performance in the third quarter, with all divisions contributing to growth..."
22 October 2013 | By AstraZeneca
SELECT-1 will be the first Phase III study to investigate whether a MEK inhibitor in combination with chemotherapy is superior to chemotherapy alone...
21 October 2013 | By College Hill
Dr Holland is an expert in biomarker-driven drug development...
21 October 2013 | By Rigaku Raman Technologies
The new Raman Probe II and Economy Probe will enable customers to significantly improve routine laboratory Raman spectroscopy...
21 October 2013 | By Sagefrog Marketing Group, LLC
In the immediate term, the combined capabilities create a powerful offering in finding, engaging and paying Investigators...
21 October 2013 | By IDT Biologika
IDT Biologika GmbH, a major developer of pharmaceutical technology and a producer of proprietary and third-party biopharmaceuticals and viral and bacterial vaccines, and Oncotec Pharma Produktion announced investments dedicated to increasing their respective production capacities.
18 October 2013 | By Penn Pharma
Penn Pharma will be meeting with professionals at the world’s leading pharmaceutical networking event, CPhI/ICSE World-Wide, from 22nd October – 24th October in Frankfurt...
18 October 2013 | By Johnson & Johnson
Dr. McClellan has more than two decades of public service and academic research experience...
The study met its primary endpoint, showing a statistically significant greater reduction in fibromyalgia pain...
18 October 2013 | By GlaxoSmithKline
The application is based primarily on results from an international, multi-centre, randomised Phase III study of ofatumumab...
18 October 2013 | By Boehringer Ingelheim
"The improvements in lung function and quality of life seen with once-daily Striverdi® Respimat® are remarkable..."
18 October 2013 | By Abbott
One in five Medicare patients is readmitted to a hospital each year at an estimated cost of $17.5 billion annually...
17 October 2013 | By Pfizer
Label now includes information on use of Prevenar 13 in preterm infants, children and adolescents with sickle cell disease...
16 October 2013 | By Merck
Company confirms development program for investigational once daily (QD) dosing regimen of ISENTRESS...
